Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry

Overview of attention for article published in Journal of Cancer Research and Clinical Oncology, August 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (89th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

So far, Altmetric has seen 1 public wall post.

#PublicaSalutIB Influència de l'estat d'HER2 en el benefici del ramucirumab i paclitaxel com a tractament de segona línia per a…

This page shows the most recent Facebook posts that mention this research output.

Click here to find out how to access more activity.